Morphotek Inc. Awarded $2.5 Million from U.S. Department of Defense to Continue Development of Therapeutic Antibodies Against Microbial Bioweapons

EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has been awarded a contract for $2.5 million from the U.S. Department of Defense (DOD) to support the continuing development of monoclonal antibody (mAb) therapies against staphylococcal-derived toxins and pathogenic staphylococcal strains. In February 2008, Morphotek was awarded $1.7 million in funding to support the initial development of these mAb therapies.

Back to news